Summary: The combination of beclomethasone, formoterol and glycopyrronium bromide in one pMDI-type inhaler represents the first registered triple therapy (ICS/LABA/LAMA) for the treatment of COPD. The results of clinical trials demonstrate the efficacy of triple therapy in patients with more severe forms of COPD. A 20% reduction in the risk of moderate to severe exacerbation has been found in patients receiving triple therapy compared to the ICS/LABA combination and LAMA monotherapy. Triple therapy reduces the rate of moderate to severe exacerbations also in comparison with double bronchodilatation (LABA/LAMA) by 15%. The safety profile of triple therapy is typical for individual drugs used to treat obstructive lung diseases included in the combination. There was no increased risk of pneumonia in patients receiving triple therapy compared to the LABA/LAMA combination. The advantage of triple therapy administered from one inhaler is also represented by the improvement of compliance and the reduction of the risk of inhalation errors, especially frequent when inhaled medications are given with different inhalers. In conclusion, the first approved drug in one inhaler for triple therapy ICS/LABA/LAMA, a combination of beclomethasone, formoterol and glycopyrronium bromide, represents a valuable complement to available methods of COPD therapy.